Mesa Laboratories Inc income statement

In fiscal 2026, Mesa Laboratories Inc reported revenue of $249m, up 3.4% on the year before, operating income of $18.5m (a 7.4% margin) and net income of $6.7m, or $1.21 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mesa Laboratories Inc: income statement, annual
Fiscal year	2011Mar 2011	2012Mar 2012	2013Mar 2013	2014Mar 2014	2015Mar 2015	2016Mar 2016	2017Mar 2017	2018Mar 2018	2019Mar 2019	2020Mar 2020	2021Mar 2021	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026	LTMJun 2026
Revenue	34	40	46	53	71	85	94	96	103	118	134	184	219	216	241	249	250
Cost of revenue	15	16	18	21	28	33	40	42	42	52	47	75	85	83	90	91	89
Gross profit	20	24	29	32	43	51	53	55	61	65	87	109	134	133	151	158	160
Research and development	1	1	2	2	3	4	4	4	4	6	10	16	20	19	20	20	20
Selling and marketing	4	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
General and administrative	5	5	9	11	17	24	23	26	31	38	46	60	72	73	73	79	78
Operating income	10	12	13	12	16	16	16	2	10	8	12	5	3	−272	16	19	22
Interest expense	—	—	—	—	—	—	—	2	2	6	8	4	5	6	12	11	11
Income before tax	10	12	13	13	15	16	14	0	9	4	2	4	−0	−276	6	12	9
Income tax	4	4	5	4	6	4	3	3	1	2	−1	2	−1	−21	8	5	5
Net income	6	8	8	9	10	11	11	−3	7	2	3	2	1	−254	−2	7	5
Diluted EPS	$1.86	$2.29	$2.35	$2.49	$2.63	$2.97	$2.91	−$0.79	$1.86	$0.41	$0.64	$0.35	$0.17	−$47.20	−$0.36	$1.21	$0.85
Diluted shares (average)	3m	3m	4m	4m	4m	4m	4m	4m	4m	4m	5m	5m	5m	5m	5m	6m	6m
EBITDA	12	15	17	16	22	23	25	12	19	21	30	30	37	−268	22	24	28

US$ millions unless shown otherwise. Fiscal quarters.

Mesa Laboratories Inc: income statement, quarterly
Quarter	2025 Q2Sept 2024	2025 Q3Dec 2024	2025 Q4Mar 2025	2026 Q1Jun 2025	2026 Q2Sept 2025	2026 Q3Dec 2025	2026 Q4Mar 2026	2027 Q1Jun 2026
Revenue	58	63	62	60	61	65	64	60
Cost of revenue	22	23	24	23	23	23	22	21
Gross profit	35	40	38	37	37	42	42	39
Research and development	5	5	5	5	5	5	5	5
General and administrative	17	18	21	18	18	19	24	17
Operating income	4	6	1	3	5	8	3	7
Interest expense	3	3	3	2	3	3	3	2
Income before tax	4	−2	0	7	2	5	−2	4
Income tax	0	−1	8	2	−0	1	3	2
Net income	3	−2	−7	5	2	4	−4	3
Diluted EPS	$0.63	−$0.31	−$1.30	$0.85	$0.45	$0.65	−$0.74	$0.49
EBITDA	5	7	3	4	6	9	4	8

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MLAB vs SDGR MLAB vs MRVI CTKB vs MLAB FLGT vs MLAB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Mesa Laboratories Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mesa Laboratories Inc.